Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-069231
Filing Date
2025-05-12
Accepted
2025-05-12 16:14:43
Documents
73
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q kpti-20250331.htm   iXBRL 10-Q 2455028
2 EX-3.1 kpti-ex3_1.htm EX-3.1 134764
3 EX-10.1 kpti-ex10_1.htm EX-10.1 35932
4 EX-10.2 kpti-ex10_2.htm EX-10.2 26965
5 EX-31.1 kpti-ex31_1.htm EX-31.1 12679
6 EX-31.2 kpti-ex31_2.htm EX-31.2 12700
7 EX-32.1 kpti-ex32_1.htm EX-32.1 8083
8 EX-32.2 kpti-ex32_2.htm EX-32.2 8088
  Complete submission text file 0000950170-25-069231.txt   9271898

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kpti-20250331.xsd EX-101.SCH 1307522
76 EXTRACTED XBRL INSTANCE DOCUMENT kpti-20250331_htm.xml XML 1391968
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

EIN.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36167 | Film No.: 25935012
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)